What is Ironwood Pharmaceuticals's market cap?

Ironwood Pharmaceuticals (IRWD) has a market capitalization of $643.6M and trades on NASDAQ.

What is Ironwood Pharmaceuticals's revenue and profitability?

Ironwood Pharmaceuticals generated $361.5M in trailing twelve-month revenue with net income of $102.2M, representing a net margin of 28.3%. Gross margin stands at 99.2%. These figures are based on the Q1 2026 filing.

Who are Ironwood Pharmaceuticals's competitors?

Ironwood Pharmaceuticals's key competitors include Ardelyx, Inc., Bausch Health Companies, Neurocrine Biosciences Inc, and others. These companies compete in similar markets and product categories.

Who does Ironwood Pharmaceuticals partner with?

Ironwood Pharmaceuticals's notable partners include AbbVie Inc., AstraZeneca AB, Astellas Pharma Inc., and others.

What subsidiaries does Ironwood Pharmaceuticals have?

Ironwood Pharmaceuticals's subsidiaries include VectivBio Holding AG.

Where is Ironwood Pharmaceuticals headquartered?

Ironwood Pharmaceuticals is headquartered in United States of America and employs approximately 267 people. It has been publicly traded since 2010.

Ironwood Pharmaceuticals

IRWD

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal (GI) and rare diseases.

Market cap

$643.64M+377%

Revenue$361.5M+13.8%

Net income$102.2M+416%

EPS (diluted)$0.60+386%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$106.5MBeat by $14.4M EPS$0.24Beat by $0.17

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$114.8M

EPS estimate$0.32

Financials

Q1 2026

Income statement

See full

Revenue$106.5M+159%

Operating income$72.6M+349%

Net income$40.8M+209%

EPS (diluted)$0.24+204%

Balance sheet

See full

Cash & equivalents$220.5M+103%

Total debt$212.4M+1,323%

Total equity-$217.1M+35.0%

Total assets$434.6M+32.8%

Cash flow

See full

Operating cash flow$5.1M-74.3%

Valuation & ratios

Valuation

See full

Market cap$643.64M+377%

Enterprise value$635.52M+154%

P/E6.3×—

P/S1.8×+1.4×

Profitability

See full

Operating margin55.4%+38.7pp

Net margin28.3%+22.3pp

Returns & leverage

See full

Current ratio1.4×-1.9×

Segments

By product

See full

Royalty$800.0K0.0%

Collaborative Arrangement Development And Commercialization Agreements$200.0K-60.0%

Competitors

By market cap

Neurocrine Biosciences$17.7B+34.0%

Ionis Pharmaceuticals$9.2B+41.1%

Rhythm Pharmaceuticals, Inc.$7.3B+28.8%

Mirum Pharmaceuticals, Inc.$7.0B+173%

Bausch Health Companies$1.7B-34.3%

Ardelyx$1.2B+22.1%

Rigel Pharmaceuticals$691.8M+93.6%

Ironwood Pharmaceuticals$643.6M+398%

By revenue growth

Rhythm Pharmaceuticals, Inc.+58.7%

Mirum Pharmaceuticals, Inc.+50.2%

Rigel Pharmaceuticals+47.6%

Neurocrine Biosciences+28.6%

Ardelyx+18.2%

Ironwood Pharmaceuticals+13.8%

Bausch Health Companies+8.2%

Ionis Pharmaceuticals-7.4%

By net margin

Rigel Pharmaceuticals121.51%+103pp

Ironwood Pharmaceuticals28.26%+38.4pp

Neurocrine Biosciences21.55%+8.9pp

Bausch Health Companies-1.88%-9.1pp

Ardelyx-13.58%+9.9pp

Ionis Pharmaceuticals-64.7%-36.3pp

Rhythm Pharmaceuticals, Inc.-93.33%+29.9pp

Mirum Pharmaceuticals, Inc.-140.24%-120pp

Profile

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal (GI) and rare diseases. The company's core value proposition centers on its market-leading treatment for irritable bowel syndrome with constipation and its pipeline of next-generation peptide analogs for short bowel syndrome. Ironwood leverages strategic global partnerships to maximize the reach of its commercial products while maintaining a specialized focus on GI development and commercialization in the United States.

Competitive position

Ironwood maintains a leading position in the U.S. IBS-C market with the number one prescribed branded treatment. The company utilizes a hybrid model of direct U.S. commercialization and global out-licensing to established pharmaceutical leaders.

GeographiesUnited States, Canada, Mexico, Japan, China, Europe

Customer segmentsPatients, Healthcare Professionals, Pharmaceutical Partners

Business modelProduct-based, Licensing and Royalties, Collaborative R&D

SuppliersContract Development and Manufacturing Organizations (CDMOs), Active Pharmaceutical Ingredient (API) suppliers, Clinical research organizations

CustomersPharmaceutical wholesalers, Retail pharmacy chains, Medicare and Medicaid programs, Commercial insurance payors

CountryUnited States of America

Listed2010

Employees267.0

CEOThomas A. McCourt

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteironwoodpharma.com

FilingsSEC EDGAR

Ask your AI about Ironwood Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ironwood Pharmaceuticals's market cap?: Ironwood Pharmaceuticals (IRWD) has a market capitalization of $643.6M and trades on NASDAQ.
What is Ironwood Pharmaceuticals's revenue and profitability?: Ironwood Pharmaceuticals generated $361.5M in trailing twelve-month revenue with net income of $102.2M, representing a net margin of 28.3%. Gross margin stands at 99.2%. These figures are based on the Q1 2026 filing.
Who are Ironwood Pharmaceuticals's competitors?: Ironwood Pharmaceuticals's key competitors include Ardelyx, Inc., Bausch Health Companies, Neurocrine Biosciences Inc, and others. These companies compete in similar markets and product categories.
Who does Ironwood Pharmaceuticals partner with?: Ironwood Pharmaceuticals's notable partners include AbbVie Inc., AstraZeneca AB, Astellas Pharma Inc., and others.
What subsidiaries does Ironwood Pharmaceuticals have?: Ironwood Pharmaceuticals's subsidiaries include VectivBio Holding AG.
Where is Ironwood Pharmaceuticals headquartered?: Ironwood Pharmaceuticals is headquartered in United States of America and employs approximately 267 people. It has been publicly traded since 2010.